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The National Toxicology Program (NTP)
hosted the workshop “Hormonally Induced
Reproductive Tumors—Relevance of Rodent
Bioassays” on 22–24 May 2006 in Raleigh,
North Carolina, to discuss the adequacy of
rodent models used in the 2-year bioassay by
the NTP for detecting certain reproductive
tumors. This workshop is the third in a series of
activities associated with the NTP Roadmap to
critically evaluate the NTP testing program and
determine whether any refinements or new
strategies are needed to maximize its impact on
public health (NTP 2005c). More than
100 people from academia, industry, govern-
ment, and nonproﬁt organizations attended the
workshop, including an invited panel of 55 sci-
entists with expertise in endocrinology, cancer
biology, reproductive toxicology, statistics, and
other related ﬁelds. The workshop opened with
a series of presentations on each of the target
tumors from the perspective of clinical and epi-
demiologic studies, mode(s) of action, and
rodent models. To address the workshop’s
objectives, the invited panels also met in tumor
site-speciﬁc breakout groups and summarized
their discussions in a plenary session. The
workshop agenda, presentations, background
materials, roster of the invited panel and other
attendees, and public comments can be found
on the NTP website (http://ntp.niehs.nih.gov;
see “Meetings & Workshops” or directly at
http://ntp.niehs.nih.gov/go/18592).
The workshop’s overall objective was to
determine the utility and relevance to human
disease outcome of experimental rodent mod-
els for evaluating four types of reproductive
tumors (ovary, mammary gland, prostate, and
testis) with known or presumed hormonal eti-
ologies. The NTP is interested in these issues
because of concern that current rodent models,
including those used by the NTP, may not
adequately detect carcinogens that act via the
endocrine system or other nongenotoxic
modes of action. Tumors of the mammary
gland, ovary, prostate, and testis were selected
for evaluation because of their significant
human morbidity and mortality and concern
that currently used models are not optimal for
addressing these tumor types. In some cases,
the modes of action thought to cause these
types of tumors in rodents are not believed rel-
evant to humans. For example, atrazine-
induced mammary gland tumors in the
Sprague-Dawley rat are attributed to pre-
cocious reproductive senescence that results
from atrazine’s effects on neuroendocrine
function [U.S. Environmental Protection
Agency (EPA) 2000]. In certain strains of
rats, reproductive senescence in females is
characterized by a state of persistent estrus and
high levels of estrogen, which may increase
the risk of tumor formation in estrogen-
responsive tissues. This mode of action is gen-
erally not considered relevant to humans
because circulating levels of endogenous
estrogen decrease during menopause.
In other cases, the rodent species and
strains currently used in NTP chronic bioas-
says (F344/N rat and B6C3F1/N mouse) are
suspected to be poor models because they
either do not develop a speciﬁc type of tumor
or have a high spontaneous tumor incidence.
Either situation can make detecting a chemi-
cally induced effect difﬁcult. For example, in
NTP chronic bioassays, prostate tumors are
rarely observed in control animals and have
never been clearly associated with a chemical
exposure, suggesting that the current models
are not sensitive for detecting potential
human prostate carcinogens. However, this
problem is not speciﬁc to the F344/N rat and
B6C3F1/N mouse, as no conventional rodent
models are considered ideal to assess chemi-
cally induced prostate cancer (NTP 2006e).
At the other extreme are testicular Leydig cell
tumors in the F344/N rat. The spontaneous
incidence in control animals is so high
(∼ 70–90%) that it can be difﬁcult to detect a
statistically significant increase above back-
ground (NTP 2005a). The conventional
rodent models may also be poor predictors of
human response because of signiﬁcant differ-
ences between rodents and humans in tumor
prevalence, anatomy, or tumor histology. 
Following are brief summaries of the break-
out group discussions, which focus on the over-
all utility of currently used rodent models and
what is known regarding endocrine-related
modes of action. Presentations and breakout
group reports that provide the foundation for
these summaries are available on the NTP
website (see previously mentioned websites).
It is worth noting that all the breakout groups
struggled with some of the same general
issues. For example, they were unsure how to
evaluate the predictiveness of rodent models
for identifying potential human carcinogens
given the limited number of agents ade-
quately evaluated in humans. In addition, the
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The National Toxicology Program (NTP) is currently reviewing its research portfolio as part of its
efforts to implement the NTP Roadmap to achieve the NTP Vision for the 21st century. This
review includes a recent workshop, “Hormonally Induced Reproductive Tumors—Relevance of
Rodent Bioassays,” held 22–24 May 2006, that was organized to determine the adequacy and rele-
vance to human disease outcome of rodent models currently used in the 2-year bioassay for four
types of hormonally induced reproductive tumors (ovary, mammary gland, prostate, and testis). In
brief, none of the workshop’s breakout groups felt the currently used models are sufficient. For
some types of tumors such as prostate, no adequate animal models exist, and for others such as
ovary, the predominant tumors in humans are of different cellular origins than those induced by
chemicals in rodents. This inadequacy of current models also applies to the testis, although our
more complete understanding of the responses of Leydig cells to hormonal changes in rats may
prove predictive for effects in humans other than cancer. All breakout groups recommended that
the NTP consider modifying its testing protocols (i.e., age at exposure, additional end points, etc.)
and/or using alternative models (i.e., genetically engineered models, in vitro systems, etc.) to
improve sensitivity. In this article we briefly review the workshop’s outcome and outline some
next steps forward in pursuing the workshop’s recommendations. Breakout group reports and
additional information on the workshop, including participants, presentations, public comments
and background materials, are posted on the NTP website. Key words: animal models, breast,
endocrine, hormone, mammary gland, National Toxicology Program, ovary, prostate, reproduc-
tive tumors, species differences, testis. Environ Health Perspect 115:1351–1356 (2007).
doi:10.1289/ehp.10135 available via http://dx.doi.org/ [Online 5 July 2007]scientific literature for both humans and
rodents often does not allow distinguishing
between endocrine hormone-induced and
endocrine system-mediated roles in the etiol-
ogy and progression of tumorigenesis.
Breakout Group Discussions
Testis. Background information: predominant
tumor types and role of the endocrine system.
The NTP selected testicular tumors for evalua-
tion because incidence of the disease is increas-
ing in men in certain regions of the world and
the there is concern that current NTP rodent
models (F344/N rat and B6C3F1/N mouse)
are not optimal for identifying potential human
testicular carcinogens (NTP 2005a). More than
90% of testicular tumors in men are germ cell
tumors, and only approximately 2% are inter-
stitial or Leydig cell tumors. In contrast, germ
cell tumors are rarely (at most) observed in
rodents, whereas spontaneous Leydig cell
tumors are extremely common in the F344/N
rat. The high background incidence of Leydig
cell tumors in the F344/N rat (~ 70–90%)
makes detecting a statistically significant
increase in these tumors in treated animals
extremely difﬁcult. Only two (ethylbenzene and
isoprene) of the more than 500 chemicals tested
in NTP chronic bioassays show clear evidence
of causing testicular adenomas in the F344/N
rat. Other rat strains, such as the Sprague-
Dawley and Wistar Han, have a lower sponta-
neous incidence of Leydig cell tumors (~ 5%),
making them potentially more sensitive models
(NTP 2005a). The B6C3F1/N mouse has a
very low incidence of spontaneous Leydig cell
tumors (< 1%) but also appears to be resistant
to developing chemically induced testicular
tumors, as none have been identiﬁed in NTP
studies. Leydig cell tumors in other strains of
mice can be induced chemically (particularly by
estrogenic agents), but generally mice are resis-
tant to the wide variety of agents known to
induce these tumors in rats, particularly the
Sprague-Dawley and Wistar (Cook et al. 1999).
In both rats and mice, luteinizing hor-
mone (LH) acts as a promoter in the develop-
ment of Leydig cell clusters, hyperplasia, and
tumors. Differences in response to LH
between the rat and human may partially
explain the greater sensitivity of rats to
develop Leydig cell tumors compared with
that in humans. In rats, chemically induced
Leydig cell tumors are usually observed after
treatment with compounds that increase LH.
In humans, a syndrome exists that can be
used for comparative purposes. Familial male
precocious puberty (FMPP) stems from a
mutation in the LH receptor, resulting in
constitutive activation. Men with this dis-
order undergo puberty at around 4 years of
age, although they have normal fertility and
lifespan. Individuals with FMPP exhibit
Leydig cell hyperplasia but are not known to
have a higher incidence of Leydig cell tumors.
Human Leydig cells have lower numbers of
LH, gonadotropin-releasing hormone agonist
(GnRH), and prolactin receptors per cell than
rodent Leydig cells, which may translate into
a reduced sensitivity of response to ligands for
these receptors. The mouse differs from both
the rat and human. The same compounds
that induce Leydig cell tumors in rats do not
typically have this effect in mice. In mice,
Leydig cell tumors have been induced by
estrogen agonists and antagonists that may be
acting directly by inducing Leydig cell prolif-
eration and indirectly by increasing LH levels
and LH receptor concentrations.
Low levels of androgens or disorders that
result in decreased androgen response are
associated with testicular tumors in rats and
men. The antiandrogen ﬂutamide is a potent
inducer of Leydig cell tumors in rats, presum-
ably through causing a rise in LH secretion.
The incidence of Leydig cell tumors in men
who have a defective androgen receptor that
makes them insensitive to androgens is con-
siderably higher than for men without this
syndrome (2.3% vs. ~ 0.00004%). Human
germ cell tumors are considered to have an
in utero origin, and androgens are required for
progression of the transformed gonocyte (fetal
germ cell) or carcinoma in situ (CIS) to a
germ cell tumor in humans. The incidence of
germ cell tumors is also higher in men with
androgen insensitivity syndrome, providing
support for the role of androgens in develop-
ment of germ cell tumors. The seemingly
complex relationship between androgens and
germ cell tumors may be a function of the rela-
tively high amount of androgen required for
normal reproductive tract development and
differentiation of germ cells versus the lower
amount needed for germ cell proliferation.
Lowered androgen may aid the production of
CIS cells because of “faulty” differentiation
but still be present in sufficient amount to
allow proliferation of the CIS cells once
formed. The extent to which gonadal cell dif-
ferentiation is normal in rodents with com-
plete androgen insensitivity syndrome has yet
to be adequately addressed.
Conclusions and recommendations.
Despite differences in tumor incidence and
hormone response, rodent models are still
considered useful. The characteristics of
Leydig cell tumors and their diagnostic crite-
ria are generally similar for rodents and men,
although there may be differences in termi-
nology. For example, the term “Leydig cell
micronodule” in humans is often equated to
small adenomas in rodents (Holm et al.
2003). Germ cell tumors are too rare in
rodents to evaluate the similarities between
rodents and men. The breakout group recom-
mended that the NTP explore the 129 mouse
strain, which is predisposed to developing
male germ cell tumors, as a possible model for
germ cell tumors in men. 
CIS have both stem- and germ-cell prop-
erties and originate from undifferentiated
gonocytes because of poor function of Sertoli
and/or Leydig cells during testis development.
CIS is considered part of the testicular dysgen-
esis syndrome where environmental and
genetic factors can alter Sertoli cell function,
leading to reduced semen quality and CIS, or
decrease Leydig cell function, leading to
hypospadias and cryptorchidism. For this rea-
son, some members of this breakout group
suggested that Leydig cell nodules/hyperplasia
in the rat might serve as a surrogate marker for
germ cell tumors in men. However, the break-
out group believed that evaluation of Leydig
cell nodules/hyperplasia for this purpose
would be most informative in a cancer study
that included in utero exposure. Currently, the
NTP does not undertake in utero exposure
routinely as part of its cancer studies; there-
fore, the critical windows for development of
potential testicular dysgenesis in rodents are
not evaluated. The breakout group also
emphasized that testicular cancer is a repro-
ductive disease and men with this disease are
more likely to have cryptorchidism and low
sperm counts. For this reason, the group sug-
gested that identiﬁcation of similar outcomes
in rodents might serve as early predictors of
testicular germ cell tumor induction.
Mammary gland. Background informa-
tion: predominant tumor types and role of
the endocrine system. The NTP included
evaluation of mammary gland tumors in the
workshop because breast cancer is the most
common type of cancer in women, affecting
approximately 1 in 7. Another reason for
selecting this target site is concern that the
NTP’s current rodent models (the F344/N rat
and B6C3F1/N mouse) are not ideal for iden-
tifying potential human breast carcinogens. 
Both similarities and differences exist
between rodents and humans in terms of
tumor characteristics and diagnostic criteria.
Fibroadenoma is the predominant lesion in
some strains of rat but is not considered a pre-
malignant lesion in humans. Adenoma and
carcinoma in rats are considered to be rele-
vant to breast cancer in humans, but human
metastases can be hard to model, as mam-
mary gland carcinomas in rodents rarely
metastasize. Premalignant lesions (e.g., atypi-
cal hyperplasia) can be observed in both rats
and humans. In contrast, premalignant
lesions in the mouse do not parallel patholog-
ical changes in humans.
Historically, incidences of mammary
gland tumors in control animals are lower in
female mice compared with female rats (NTP
2005a). In fact, the high background inci-
dence of mammary gland tumors, particularly
fibroadenomas (~ 40–45%), in female
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NTP bioassay. From one perspective it could
be argued that this high background incidence
mimics the relatively common occurrence of
breast cancer in women (lifetime risk is
12.7%). However, from a statistical perspec-
tive, high background rates of tumors in con-
trol animals generally decrease the ability to
detect an exposure-related effect. In addition,
when a statistically signiﬁcant tumor effect is
found in test animals relative to concurrent
controls, the effect may not be considered
exposure related if it falls within the range
observed in historical controls. From a biologi-
cal perspective, even though ﬁbroadenomas are
clinically relevant, they are a benign tumor and
may not be predictive of carcinoma in women.
It is clear from both epidemiologic and
experimental animal studies that breast tumors
can have an endocrine component. In women,
an increased exposure to endogenous or syn-
thetic estrogens increases the risk of developing
the disease. Factors that lead to greater lifetime
exposure to endogenous estrogens (i.e., early
menses, late menopause, nulliparity, post-
menopausal obesity) are associated with ele-
vated risk. Older age at first full-term birth
(≥ 30 years vs. < 20 years) also increases the
risk of developing breast cancer. Exposures to
synthetic estrogens or pharmaceuticals that
contain combinations of estrogens and proges-
terones such as diethylstilbestrol, oral contra-
ceptives, and hormone replacement therapy are
also linked to increased risk. The role of other
“reproductive” hormones such as prolactin,
progesterone (when not combined with estro-
gen), and androgens thought important in
stimulating mammary cancer in certain rodent
models is less clear in breast cancer for women.
The breakout group emphasized that
nonsteroidal and nonpituitary hormones such
as insulin-like growth factor 1 (IGF-1) and
insulin may play a role in the etiology and
progression of breast cancer. What is less clear
is whether endocrine-active compounds act as
tumor initiators or promoters. For example,
ovariectomized rats do not develop mammary
gland tumors even when treated with potent
chemical carcinogens as positive control com-
pounds (Russo and Russo 1998). This ﬁnding
suggests that ovarian hormones are acting as
promoters. The breakout group noted that
tumors may arise from endocrine alterations
and genotoxicity as well as epigenetic effects. 
The endocrine differences between
rodents and women can complicate the inter-
pretation of a positive bioassay finding. For
example, prolactin is the predominant driver
of tumor development in F344 rats; however,
whether this hormone is a causative agent in
humans is not clear. The breakout group
noted that premature ovarian failure caused
by exposure to a particular agent could pro-
duce a false negative tumorigenic effect for
the mammary gland since a loss of ovarian
hormones and function results in mammary
tissue regression.
Conclusions and recommendations. In the
absence of an ideal model, the existing rodent
models are useful for identifying the potential
ability of a compound to induce biological
change and serve a useful screening function to
identify potential carcinogens. More specifi-
cally, the rat is considered to be a better model
than the mouse for the purpose of identifying
potential human carcinogens because mice are
generally more resistant to developing chemi-
cally induced mammary gland tumors. For
example, the Carcinogenic Potency Database
(CPDB) identiﬁes only 24 chemicals associated
with mammary gland tumors in mice com-
pared with 102 in rats (Gold et al. 2001). In
the traditional NTP bioassay where both rats
and mice are tested for each compound,
11 chemicals are identiﬁed as having “some” or
“clear” evidence of mammary gland tumors in
mice, whereas 27 are identiﬁed as such in rats
(and 4 are positive in both). However, without
a better understanding of the underlying biol-
ogy and the relevance of changes in rodents to
changes in humans, the full predictive value of
these models cannot be realized.
Furthermore, the standard NTP bioassay
may miss important opportunities for identify-
ing compounds capable of causing breast can-
cer. The group recommended considering
experimental designs that address relevant expo-
sure windows (e.g., in utero exposures, expo-
sures during puberty, exposures before a ﬁrst
full-term pregnancy) and that distinguish
between pre- and postmenopausal risk to detect
more agents of potential human concern.
Prostate. Background information:
predominant tumor types and role of the
endocrine system. Prostate tumors were cho-
sen for evaluation at the workshop because
prostate cancer is the most common cancer in
males in the United States and the third most
common cancer worldwide. In addition, it is
clear that current, conventional rodent models
are not useful for identifying prostate carcino-
gens. Unlike the human condition, sponta-
neous prostate cancer is very rare in rodents,
including the F344/N rat and B6C3F1/N
mouse used by the NTP (2005a). In a survey
of almost 4,550 rats and mice used as controls
in NTP inhalation or feed studies only 1 carci-
noma and 17 adenomas were detected (NTP
2006e). No substances have been identiﬁed as
causing prostate tumors in NTP studies.
There is likewise currently little compelling
evidence for environmental agents causing
prostate cancer in humans.
In addition to differences in spontaneous
tumor incidences, the anatomy of the prostate
gland in humans and rodents is considerably
different (i.e., the rodent prostate is lobular
and the human prostate is not). Also, the
diagnostic criteria and terminology used to
describe prostate histopathology in experi-
mental biology, toxicology, and clinical medi-
cine differ between rodents and humans. For
example, NTP and other veterinary toxicol-
ogy pathologists do not use the diagnostic
term “prostatic intraepithelial neoplasia” or
“Gleason scores” that are used in experimen-
tal biology and in clinical practice because
proliferative prostate lesions are so rare in
their rodent models.
Prostate tumors can be induced in rodents
via treatment with several compounds, includ-
ing androgens, estrogens, and certain muta-
genic agents. With respect to endocrine
modulation, perinatal treatment with estrogen
or long-term treatment with testosterone or
testosterone and estradiol can induce prostate
adenocarcinomas and carcinomas although
the tumor type and incidence are species,
strain, and protocol dependent. The evidence
in humans is less clear regarding whether an
altered endocrine environment can cause
prostate tumors although numerous studies
link elevated levels of IGF-1 with prostate can-
cer. Androgens appear to play a “permissive”
role in the development of prostate tumors.
Conclusions and recommendations.
Despite the differences in prostate anatomy
and pathology between humans and rodents,
the breakout group felt it would be prudent
to consider prostatic inﬂammation and hyper-
plasia in rodent models relevant for human
diseases of the prostate such as benign prosta-
tic hyperplasia (BPH) and prostate tumors.
The group also suggested NTP investigate the
various genetically engineered models that
have been developed to study factors related
to the pathogenesis of experimental prostate
cancer. These models, however, are generally
driven by molecular mechanisms not neces-
sarily relevant or specific to human prostate
cancer (e.g., promotion of SV40 viral inserts).
To improve the ability to detect environmen-
tal factors that may contribute to prostate
cancer, the breakout group encouraged the
NTP to consider dosing animals in the early
postnatal period during prostate duct devel-
opment and to search for rodent strains more
sensitive to development of prostate cancer.
More extensive histopathology of the prostate
was also recommended, as chemically induced
preneoplastic changes may have value for
assessing human carcinogenic potential.
Ovary. Background information: predomi-
nant tumor types and role of the endocrine
system. Although the life-time risk of develop-
ing ovarian cancer is not high (~ 1.5%), it is
the most lethal female reproductive system
cancer. The absence of a screening test and a
lack of knowledge about the symptoms of
ovarian cancer result in a diagnosis that typi-
cally does not occur until the later stages of the
disease when survival drops to 20–30%.
Hormonally induced reproductive tumors
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rodent ovarian pathophysiology limit the
applicability of conventional rodent models for
understanding the causes, progression, and
therapeutic interventions of this disease.
Approximately 90% of ovarian cancers in
women originate from the surface epithelium.
In contrast, granulosa cell tumors are the most
common type of rodent ovarian tumor, and
spontaneous epithelial cell tumors are only
rarely noted. With exception of the mutagen
7,12-dimethylbenz[a]anthracene (DMBA),
chemical exposures are not known to cause
epithelial ovarian tumors in rodents. In addi-
tion, spontaneous and nonmutagenic chemi-
cally induced rodent ovarian tumors are
generally benign. The low incidence of sponta-
neous ovarian tumors in rats and mice may
limit the utility of the rodent bioassay for
detecting possible human ovarian carcinogens
(NTP 2005a). Historically the incidences for
various types of ovarian tumors in control ani-
mals for both the F344/N rat and B6C3F1/N
mouse are typically < 1% (NTP 2005a,
2006e). Only 10 chemicals show “some” or
“clear” association with ovarian tumors in
NTP studies, and none are reported carcino-
genic in the rat (NTP 2006e), suggesting that
ovarian tumors are not readily induced by
chemical exposures in NTP model systems. 
The breakout group believed the evidence
suggests that epithelial ovarian tumors in
women can result from an altered endocrine
environment. For example, the risk of develop-
ing ovarian cancer increases around the time of
menopause and for women taking estrogen-
only hormone replacement therapy. In con-
trast, increases in the number of live births and
in oral contraceptive use are associated with
decreased risk. Elevated levels of circulating
gonadotropins are clearly associated with stro-
mal tumor development based on studies using
genetically engineered rodent models such as
the inhibin-α knockout, estrogen receptor-α
knockout, and transgenic animals that over-
express LH-β. Ovarian germ cell tumors are
not associated with an altered endocrine envi-
ronment; however, the mechanisms of toxicity
for compounds that induce ovarian tumors in
rodents are typically unknown or unclear. 
Conclusions and recommendations.
Despite significant differences in ovarian
tumors between humans and rodents, the
breakout group thought certain ovarian obser-
vations in rodent bioassays should be assumed
relevant for humans. For example, elevated
circulating gonadotropins and loss of ovarian
hormones should be considered relevant
because they are similar to the endocrine status
of menopausal women when most ovarian
cancers occur. Other ﬁndings such as ovarian
atrophy are good predictors of ovarian failure
but not ovarian cancer. The breakout group
also identiﬁed several preneoplastic events that
NTP could consider evaluating for predictive-
ness of human response, including loss of con-
tact inhibition, stratification of the surface
epithelium, loss of p53, loss of phosphatase
and tensin homolog (PTEN), and overexpres-
sion of phospho-AKT in epithelial cells. The
group discussed several recently developed
genetically engineered models [i.e., p53 and
retinoblastoma (Rb) conditional knock-out,
K-ras activation, and PTEN loss] that may be
useful but have not been evaluated for their




Use alternative models (i.e., genetically
engineered, in vitro, etc.) to develop sensitive
models for detecting specific types of tumors.
NTP perspective. The appeal of using alterna-
tive disease-speciﬁc models is obvious. In many
cases, these models are assumed to be better at
identifying carcinogens (at least in rodents)
than the conventional models used by the
NTP. However, the NTP must maintain a bal-
ance between retaining the original goal of the
chronic bioassay as a general screen for identify-
ing potential carcinogens and investing
resources into developing and using disease-
specific models. Clearly, it is not feasible to
study every compound in both conventional
and disease-speciﬁc models; however, there is a
compromise strategy. One of the major goals of
the NTP Roadmap is to identify markers that
are indicative of disease progression and incor-
porate them into prechronic or other prelimi-
nary studies. Findings from these studies might
then trigger using a specialized model or study
design. This approach is not new for the NTP
but rather would expand its current practice.
For example, the NTP is using the transgenic
mouse model rasH2 in 6-month cancer studies
for a number of polybrominated diphenyl ether
(PBDE) congeners because the thyroid is a
known target for the PBDEs and these trans-
genic models detect chemically induced thyroid
tumors (NTP 2006f). 
Identifying appropriate alternative models
is especially important for prostate and ovarian
cancers because the conventional rodent mod-
els are not predictive for these tumor types.
The NTP has used the transgenic adenocarci-
noma of the mouse prostate (TRAMP) model
to address the impact of dietary antioxidants
and dietary restriction on prostate cancer devel-
opment (Suttie et al. 2005; Tam et al. 2006).
Current studies generally focus on the ability of
substances to inhibit prostate cancer develop-
ment, and the NTP needs perhaps to place a
greater emphasis on exploring the use of the
TRAMP and other models to identify sub-
stances that enhance prostate carcinogenesis.
Include additional endocrine responsive
end points. NTP perspective. All the breakout
groups had suggestions for preneoplastic
responses or molecular markers that could
potentially be included in prechronic studies.
With respect to hormone-mediated tumors,
the NTP is most interested in markers that
are predictive for tumorigenesis and relevant
to human disease. Suggested endocrine
responsive assays and end points include
in vitro assays to assess estrogen or androgen
receptor binding, some of the short-term
screens being evaluated by the U.S. EPA as
part of its Endocrine Disruptor Screening
Program (U.S. EPA 2006), and whole mounts
of mammary glands. In addition, the mam-
mary and prostate breakout groups both iden-
tified IGF-1 as an important stimulant and
potentially useful marker of tumorigenic
response. In the long-term, the NTP would
like to include in vitro assays that screen for
potential endocrine activity in its High
Throughput Screening Initiative (see http://
ntp.niehs.nih.gov/go/28213 for more infor-
mation on this initiative). In the short-term,
the NTP foresees more routine assessment of
in vivo endocrine end points, such as whole
mounts of mammary glands, when prelimi-
nary data suggest an endocrine mode of
action or effect.
The NTP will consider incorporating
additional end points into prechronic studies
to better characterize end points of other
environmentally induced diseases or biologi-
cal processes related to disease etiology histor-
ically not addressed in NTP studies. For
example, the goal of another NTP workshop,
“Biomarkers for Toxicology Studies,” is to
identify biomarkers for carbohydrate/lipid
metabolism and lung and cardiac functions
and evaluate their utility for inclusion in
rodent toxicology studies (NTP 2006d). The
NTP is still in the process of formally evaluat-
ing the most promising end points to include
routinely in prechronic or other preliminary
studies. The NTP intends to make these deci-
sions over the next 2 years when additional
NTP Roadmap activities are completed. As in
the past, the inclusion of nonroutine end
points will be done on a case-by-case basis. 
It is worth noting that the NTP has previ-
ously used results from short-term studies to
formulate predictions on carcinogenic poten-
tial. For example, the chemical diazoamino-
benzene (DAAB) is considered a reasonably
anticipated human carcinogen even though it
has never been tested in a chronic bioassay,
because metabolism studies showed that
DAAB metabolizes to benzene and aniline,
both known human carcinogens (Bordelon
et al. 2005; NTP 2005b). Similarly, the NTP
does not consider 1,4-butanediol to be carcino-
genic in animals because it rapidly metabolizes
to γ-hydroxybutyric acid, which did not show
evidence of carcinogenic potential when
tested by the NTP (Irwin 2006).
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perspective. The inadequacy of the F344/N rat
as a model for testicular cancer was a major
issue for the testicular tumor breakout group.
The high background incidence of Leydig cell
tumors in the F344/N makes it a very insensi-
tive model for detecting chemically induced tes-
ticular tumors. Moreover, U.S. EPA testing
guidelines do not recommend use of rats with
low fecundity, such as the F344, for studies
evaluating reproduction (U.S. EPA 1998). The
NTP held a workshop in June 2006 speciﬁcally
to address the issue of rodent strain and stock
selections (NTP 2005a). The participants in
that workshop strongly recommended that the
NTP discontinues use of the F344/N because
of its high background incidences of certain
types of tumors (i.e., Leydig cell tumors and
mononuclear cell leukemia), unresolved issues
regarding its declining fertility, occurrence of
sporadic seizures, and chylothorax. All these
conditions are prevalent in the speciﬁc breeding
colony maintained for NTP studies. Shortly
after the workshop, the NTP discontinued use
of the NTP F344/N rat in all new studies and
began using a commercial source of the F344
(F344/NTac) as a short-term solution. The
NTP originally intended to use an isogenic
(inbred or F1 hybrid) rat strain to maximize
reproducibility in tumorigenic response over
time and facilitate genetic monitoring and
interpretation of subsequent mechanistic stud-
ies (King-Herbert and Thayer 2006). However,
the NTP is reconsidering this position so that it
might use the same strain in studies for cancer,
reproduction, or other types of toxicity. Using
the same strain for all NTP studies would mini-
mize the need to conduct multiple preliminary
and toxicokinetic studies and enhance compa-
rability across study end points.
The NTP recognizes that any particular
strain or stock will likely have some undesir-
able characteristic (e.g., exceptionally low or
high incidence for a specific tumor type,
known insensitivity to certain exposures, lack
of a historical data set, poor model for non-
cancer studies). The issue of strain selection is
only a question of which rodent model to use
when very little or no toxicity data are avail-
able for a substance. As with end point selec-
tion, NTP studies are sufficiently flexible to
allow the use of the most appropriate strain or
model, and historically the NTP has followed
this practice. For example, NTP studies might
use a rat strain other than the F344/N if exist-
ing information indicates a need or consider-
able work has been done in another strain as
long as there is no indication that the alterna-
tive model is inappropriate (NTP 2006b,
2006c). Previous work with an alternative
strain can be used to ensure that the strain
selected is responsive to a particular substance
and can often negate the need for the NTP to
conduct dose-ﬁnding studies. The NTP also
tries to avoid using a strain known to be a
poor model for a particular mode of action or
target site for toxicity when such information
is available for a given substance. For example,
the NTP used the Sprague-Dawley rat in
recent multigenerational studies for genistein
because it is a better model for substances that
may impact reproductive function than the
F344/N rat (NTP 2006a). The major hesita-
tion with moving away from routine use of
the F344 rat is whether a new strain might be
less sensitive. For this reason the NTP will
obtain as much existing information as possi-
ble on comparative carcinogenic responses in
the new strain(s) and the F344 rat. 
The current top candidates to replace the
F344/N rat are the Wistar Han and Sprague-
Dawley rats, both outbred strains. The Wistar
Han rat is appealing because it has excellent
survival at 2 years of age, a large amount of
data on control animals is available from its
use in the pharmaceutical industry, and it has
a relatively low spontaneous tumor profile.
However, the NTP is concerned that the
Wistar Han may not be a sensitive model for
detecting mammary gland carcinogens
(Ahlers et al. 1998) and toxicants that act
through the aryl hydrocarbon receptor
(Simanainen et al. 2004). 
Although the NTP uses the Sprague-
Dawley rat for reproductive studies, it previ-
ously was not seriously considered as a model
for the chronic bioassay because available his-
torical control data showed a low 2-year inci-
dence for survival (~ 40%). However, recent
studies show that the stock of Sprague-Dawley
maintained since the 1970s by the National
Center for Toxicological Research (NCTR) of
the Food and Drug Administration has an
acceptable 2-year survival (62–86% for males
and 43–64% for females; NTP 2006a). A sec-
ond possibility is the Harlan Sprague-Dawley
that has been used successfully in a number of
recent NTP studies on 2,3,7,8-tetrachloro-
dibenzo-p-dioxin (TCDD) and other “dioxin-
like” chemicals (NTP 2006b, 2006c). 
Evaluate the importance of developmental
programming in hormonally dependent issues
leading to preneoplastic events and tumors.
Overall, the breakout groups felt that in utero
and lactational exposures could be added to
the chronic bioassay depending upon what is
known about the mode(s) of action or other
endocrine-related effects of the particular sub-
stance under study. For detecting some tumor
types such as testicular germ cell tumors, this
recommendation was especially strong. The
mammary gland group felt that any known
developmental effects associated with a sub-
stance under study that involved endocrine
tissues, steroid receptor binding, a change in
mammary gland morphology, or altered tim-
ing of vaginal opening (an index of puberty)
should trigger consideration of the use of
in utero and lactational exposures. A number
of participants suggested that the NTP con-
sider using F1 animals from reproduction
studies to better evaluate carcinogenic poten-
tial of perinatal exposures (as has been done
recently for genistein) (Barrett 2006).
NTP perspective. NTP has long recog-
nized the scientific appeal of including an
in utero or perinatal exposure component in its
chronic bioassays (Chhabra et al. 1993a,
1993b). Currently, these types of studies are
generally undertaken when a substance is
known to operate via a particular mode of
action (i.e., endocrine) and/or there is evidence
that fetuses and young animals might be espe-
cially susceptible. Of course, this type of infor-
mation is unavailable for many substances
studied by the NTP, leaving open the possibil-
ity that important toxicity ﬁndings are being
missed by not addressing perinatal exposures.
The NTP recently decided to incorporate
perinatal exposure in its chronic carcinogenic-
ity studies on a more routine basis. This
means that future substances slated for car-
cinogenicity studies will include early in-life
exposure unless there is a compelling reason to
do otherwise (e.g., insufficient exposure to
pregnant women and children, lack of placen-
tal transfer or accumulation in the fetus). In
exceptional cases, the NTP may need to con-
duct multiple bioassays for a compound to
address the carcinogenic potency for various
periods of exposure (i.e., in utero only, in utero
plus adult, and adult only). However, the cost
of conducting these types of comparative
studies is prohibitive for routine practice.
NTP scientists are also considering other
approaches to address early in-life exposures,
including maintaining the F1 animals gener-
ated in reproductive studies for chronic studies
and/or strategies to evaluate perinatal expo-
sures in subchronic studies.
Any chronic or subchronic studies that
include an in utero exposure period present
challenging study design issues. For example,
dose selection will probably be much more
complicated than for the traditional chronic
study. One objective in designing studies with
perinatal exposure is to select doses that are
sufﬁciently high to challenge the animals but
not too high to terminate pregnancy, increase
mortality, induce clinical signs of toxicity, or
cause unacceptable body weight gain decre-
ments. The doses administered to accomplish
this objective may differ during critical periods
in development and adulthood. Thus, the
NTP may need to conduct multiple dose
range-finding studies and make decisions
regarding whether doses would change during
the course of the study. 
Next Steps
As part of its implementation of the NTP
Roadmap, the NTP sponsored four workshops
Hormonally induced reproductive tumors
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its testing program and determine whether
any reﬁnements or new strategies are needed
to maximize its impact on public health
(NTP 2005c). The NTP is committed to
updating its research and testing programs to
improve its ability to identify environmental
substances that may pose a threat to human
reproduction, development, and cancer
through hormonally mediated mechanisms.
The NTP has adopted some of the major
recommendations from the hormonally
induced tumors workshop and will begin
their implementation in the near future (i.e.,
more frequent inclusion of perinatal exposure
in chronic studies, better assessment of
endocrine-related responses in subchronic
studies). As discussed above, the recommen-
dation to use alternative models that might
be more sensitive for a particular effect is
already considered in the designing of NTP
studies. Other decisions, such as which rat
strain will replace the F344/N, have not been
made yet, but the issues raised at this work-
shop will play a signiﬁcant role in selection of
a new strain. The NTP appreciates the active
participation and open debate by workshop
attendees in helping identify solutions to
issues facing the program. During 2007,
NTP scientists will meet to consider the fea-
sibility and logistical, scientific and practical
considerations of the various workshops’ rec-
ommendations, and address modiﬁcations to
the testing program. Announcements of sig-
nificant program changes will be made in
future workshop reports, the NTP newslet-
ter, and at meetings of its various advisory
committees. The NTP is conﬁdent that these
changes will strengthen its research and test-
ing activities and enhance the scientiﬁc infor-
mation available for making sound decisions
that protect public health. 
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